TG Therapeutics, Inc. (NASDAQ:TGTX) has been assigned an average rating of “Buy” from the thirteen brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $28.06.

TGTX has been the topic of several analyst reports. Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. ValuEngine downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 target price (up from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th.

TG Therapeutics (NASDAQ TGTX) traded up $0.35 during trading on Thursday, hitting $8.25. 893,922 shares of the stock traded hands, compared to its average volume of 1,547,628. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. research analysts predict that TG Therapeutics will post -1.86 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Legal & General Group Plc grew its position in TG Therapeutics by 4.1% during the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 384 shares in the last quarter. Bank of America Corp DE grew its position in TG Therapeutics by 11.0% during the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,395 shares in the last quarter. BB&T Securities LLC grew its position in TG Therapeutics by 63.0% during the second quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 6,549 shares in the last quarter. UBS Group AG grew its position in TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 3,736 shares in the last quarter. Finally, First Mercantile Trust Co. grew its position in TG Therapeutics by 199.7% in the second quarter. First Mercantile Trust Co. now owns 19,179 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 12,779 shares in the last quarter. 50.45% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “TG Therapeutics, Inc. (TGTX) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/tg-therapeutics-inc-tgtx-receives-consensus-recommendation-of-buy-from-brokerages.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.